Ask AI

CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice

Gain expert-informed strategies for incorporating CDK4/6 inhibitors into the treatment of patients with early or advanced/metastatic breast cancer according to current NCCN guidelines and managing treatment-related adverse events through a certified on-demand webcast, podcast, and accompanying downloadable slides.

Share

Program Content

Activities

Aligning EBC Txn With Guidelines
Aligning Current EBC Treatment With Current NCCN Guidelines and Expert Recommendations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Aligning MBC Txn With Guidelines
Aligning Current MBC Treatment With Current NCCN Guidelines and Expert Recommendations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Managing CDK46i AEs
Managing AEs and Promoting Adherence and Persistence With CDK4/6i
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Provided by

ProCE Banner
ProCE Banner

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation